Analysis of Proseds bare-tether performance

NASA's tether experiment ProSEDS will be placed in orbit on board a Delta-II rocket in early 2003. ProSEDS will test bare-tether electron collection, deorbiting of the rocket second stage, and the system dynamic stability. ProSEDS performance will vary both because ambient conditions change along the orbit and because tether-circuit parameters follow a step by step sequence in the current operating cycle. In this work we discuss how measurements of tether current and bias, plasma density, and deorbiting rate can be used to check the OML law for current collection. We review circuit bulk elements; characteristic lengths and energies that determine collection (tether radius, electron thermal gyroradius and Debye length, particle temperatures, tether bias, ion ram energy); and lengths determining current and bias profiles along the tether (extent of magnetic self-field, a length gauging ohmic versus collection impedances, tether length). The analysis serves the purpose of estimating ProSEDS behavior in orbit and fostering our ability for extrapolating ProSEDS flight data to different tether and environmental conditions

Convective Motion in a Vibrated Granular Layer

Experimental results are presented for a vertically shaken granular layer. In the range of accelerations explored, the layer develops a convective motion in the form of one or more rolls. The velocity of the grains near the wall has been measured. It grows linearly with the acceleration, then the growing rate slows down. A rescaling with the amplitude of the wall velocity and the height of the granular layer makes all data collapse in a single curve. This can provide insights on the mechanism driving the motion.Comment: 10 pages, 5 figures submitted to Phys. Rev. Let

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol

The 2C9*3 and 2C9*2 polymorphisms of cytochrome P-450 CYP2C9 are associated with hypersensitivity to warfarin and bleeding. The effect of these polymorphisms on sensitivity to acenocoumarol is unknown. Three groups of patients, with low, medium, or high acenocoumarol-dose requirements, were studied. Age influenced the acenocoumarol sensitivity. Bearing the 2C9*3 allele was associated with the need for a lower acenocoumarol dose (odds ratio [OR], 6.02; 95% confidence interval [CI], 1.50-24.18); 80% of carriers of the 2C9*3 allele required a low dose. The 2C9*2 allele was associated with a lower acenocoumarol-dose requirement (OR, 2.70; 95% CI, 1.11-6.58) because of a reduced risk of the need for a high acenocoumarol dose (4.8% of the patients in the high-dose group carried the 2C9*2 allele versus 34.1% and 30.2%, respectively, in the medium-dose and low-dose groups). Therefore, carriers of 2C9*3 may need a low initial loading dose of acenocoumarol. Because acenocoumarol sensitivity with the 2C9*2 variant does not seem to be clinically relevant, the drug could be an alternative to warfarin in 2C9*2 carrier

Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death

The antiphospholipid syndrome (APS) is associated with thrombosis and fetal death but the pathologic mechanisms are poorly understood. Since endothelial protein C receptor (EPCR) plays a role in the anticoagulant system and in placental development, we hypothesized that anti-EPCR autoantibodies may be involved in clinical manifestations of APS and in fetal loss. The levels of immunoglobulin M (IgM) and IgG anti-EPCR autoantibodies were analyzed by enzyme-linked immunosorbent assay (ELISA) in 43 patients with APS and 43 controls. Anti-EPCR levels were higher in APS patients than in controls. Interestingly, one of the IgM anti-EPCR autoantibodies inhibited the generation of activated protein C on endothelium. Since markedly high anti-EPCR levels were found in women with fetal death, 87 patients with a first episode of unexplained fetal death were subsequently analyzed and their anti-EPCR levels were compared with 87 matched controls. We found that anti-EPCR autoantibodies constitute an independent risk factor for a first fetal death episode: the adjusted odds ratios (ORs) for anti-EPCR autoantibodies above the 95th percentile were 23.0 (95% confidence interval [CI], 2.0-266.3) for IgM and 6.8 (95% CI, 1.2-38.4) for IgG. Anti-EPCR autoantibodies can be detected in APS patients and are independent risk factors for fetal death

Charge Transport Through Open, Driven Two-Level Systems with Dissipation

We derive a Floquet-like formalism to calculate the stationary average current through an AC driven double quantum dot in presence of dissipation. The method allows us to take into account arbitrary coupling strengths both of a time-dependent field and a bosonic environment. We numerical evaluate a truncation scheme and compare with analytical, perturbative results such as the Tien-Gordon formula.Comment: 14 pages, 6 figures. To appear in Phys. Rev.

Chemically deposited In2S3–Ag2S layers to obtain AgInS2 thin films by thermal annealing.

AgInS2 thin films were obtained by the annealing of chemical bath deposited In2S3–Ag2S layers at 400 ◦C in N2 for 1 h. According to the XRD and EDX results the chalcopyrite structure of AgInS2 has been obtained. These films have an optical band gap, Eg, of 1.86 eV and an electrical conductivity value of 1.2 × 10−3 ( cm)−1

Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients

Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, represents a major cause of morbidity and mortality in patients with cancer. Low molecular weight heparins are the preferred option for anticoagulation in cancer patients according to current clinical practice guidelines. Fondaparinux may also have a place in prevention of VTE in hospitalized cancer patients with additional risk factors and for initial treatment of VTE. Although low molecular weight heparins and fondaparinux are effective and safe, they require daily subcutaneous administration, which may be problematic for many patients, particularly if long-term treatment is needed. Studying anticoagulant therapy in oncology patients is challenging because this patient group has an increased risk of VTE and bleeding during anticoagulant therapy compared with the population without cancer. Risk factors for increased VTE and bleeding risk in these patients include concomitant treatments (surgery, chemotherapy, placement of central venous catheters, radiotherapy, hormonal therapy, angiogenesis inhibitors, antiplatelet drugs), supportive therapies (ie, steroids, blood transfusion, white blood cell growth factors, and erythropoiesis-stimulating agents), and tumor-related factors (local vessel damage and invasion, abnormalities in platelet function, and number). New anticoagulants in development for prophylaxis and treatment of VTE include parenteral compounds for once-daily administration (ie, semuloparin) or once-weekly dosing (ie, idraparinux and idrabiotaparinux), as well as orally active compounds (ie, dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban). In the present review, we discuss the pharmacology of the new anticoagulants, the results of clinical trials testing these new compounds in VTE, with special emphasis on studies that included cancer patients, and their potential advantages and drawbacks compared with existing therapies